anti-CD117 CAR mRNA T cells / University of Zurich - LARVOL DELTA

Safety-Switch Engineered Anti-CD117 CAR T Cells Eradicate Human Acute Myeloid Leukemia and Hematopoietic Stem Cells (ASGCT 2023) - "Anti-CD117 CAR T cells engineered with the SB vector also showed anti-leukemic activity in a human tumor xenograft model and completely depleted healthy HSPC in immunodeficient mice reconstituted with a human hematopoiesis...Taken together, our results indicate that non-viral engineering with SB can produce functional CAR T cells even with complex vectors that include safety switch delivery. Anti-CD117 CAR T cells can lead to potent anti-tumor activity and complete eradication of HSPCs, envisioning its application prior to allo-HSCT in early clinical trials of patients with high-risk AML or Myelodysplastic Syndrome."

CAR T-Cell Therapy • Clinical • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplant Rejection • Transplantation • KIT

Anti-CD117 CAR T Cells Incorporating a Safety Switch Eradicate Acute Myeloid Leukemia and Deplete Human Hematopoietic Stem Cells (ASH 2021) - "Treatment of humanized NSG mice with two subsequent doses of anti-CD117 CAR mRNA T cells resulted in HSPC depletion...The ability to control CAR T cell pharmacokinetic properties is attractive to enable subsequent HSCT and to terminate unexpected toxicities. Anti-CD117 CAR T cells could be used prior to HSCT in refractory or minimal residual disease AML."

CAR T-Cell Therapy • Clinical • IO biomarker • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplant Rejection • Transplantation • CD34 • CD8 • HAVCR2 • KIT • LAG3 • PD-1